$ImmunityBio, Inc.(IBRX)$ π₯π₯π₯π₯π₯π₯
I closed positions and took a HUGE gain in $IBRX. It's still got more upside but hit first resistance so took gains and re-opened positions for more upside to follow. Cheers IBRXβ£οΈHappy trading ahead! BC πππ
@Tiger_comments @TigerObserver @TigerPM @TigerGPT @Daily_Discussion @TigerWire @TigerPicks
Modify on 2024-10-25 22:24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Congratulations BC! π
ImmunityBio, Inc. (IBRX) Stock Analysis
Business and Industry: ImmunityBio, Inc. is a biopharmaceutical company focused on developing potentially transformative immunotherapies for the treatment of various diseases. The company operates in the healthcare sector and is involved in the research, development, and commercialization of innovative therapies.
Earnings and Earnings Forecast: The latest earnings forecast for ImmunityBio, Inc. is as follows:
2024FY: Forecasted EPS of -0.82 USD, forecasted gross income of 10.14 million USD, and forecasted EBIT of -386.70 million USD.
2025FY: Forecasted EPS of -0.63 USD, forecasted gross income of 138.15 million USD, and forecasted EBIT of -319.42 million USD.
2026FY: Forecasted EPS of -0.35 USD, forecasted gross income of 351.05 million USD, and forecasted EBIT of -186.86 million USD.
Recent Trends and Support/Resistance Price: As of October 24, 2024, the support and resistance prices for ImmunityBio, Inc. are as follows:
Support Price: 3.64 USD
Resistance Price: 4.22 USD
Average Cost: 3.96 USD
Analyst Viewpoints and Target Price: There are currently 2 analysts covering ImmunityBio, Inc. The mean, low, and high target price estimates provided by analysts are as follows:
Mean Target Price: 6.375 USD
Low Target Price: 4.75 USD
High Target Price: 8.0 USD
The analyst recommendations for ImmunityBio, Inc. are 1 recommend and 1 hold.
Capital Flow Data: The recent 5-day capital flow data for ImmunityBio, Inc. is as follows:
10-18: Inflow of 169.59 thousand units (K)
10-21: Outflow of 33.19 thousand units (K)
10-22: Outflow of 200.0 thousand units (K)
10-23: Inflow of 217.49 thousand units (K)
10-24: Inflow of 1938.12 thousand units (K)
Stock Price: As of October 25, 2024, the stock price of ImmunityBio, Inc. is 5.2009 USD.
Profiteer Ratio: The profiteer ratio for ImmunityBio, Inc. as of October 24, 2024, is 0.803.
Recent Earnings Result: The latest earnings result for ImmunityBio, Inc. is as follows:
2024Q2: EPS of -0.20, gross profit margin of 100.00%, quick ratio of 3.54, current ratio of 3.91, total asset turnover of 0.01, return on investment of -98.15%, and net profit margin (NPM) data is not available.
It is important to note that the above analysis is not investment advice, and investors should consider the inherent risks in the stock market and fluctuations in stock prices. Please conduct further research and analysis independently before making any investment decisions.
Congratulations BC! π
πππ Awesome BC!
Awesome!